Eledon Pharmaceuticals, Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| ELDN | JNJ | |
|---|---|---|
| Market Cap | $229.16 million | $617.01 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-98,561,000 | $21.04 billion |
JNJ leads on 2 of 2 size & scale factors.
Valuation
| ELDN | JNJ | |
|---|---|---|
| P/E Ratio | — | 29.34 |
| Price / Book | 6.94 | 7.26 |
| Price / Sales | — | 6.30 |
ELDN leads on 1 of 1 valuation factors.
Profitability
| ELDN | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -298.55% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| ELDN | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.12% |
| Payout Ratio | — | 62.18 |
ELDN and JNJ split the dividend factors evenly.
Risk & Sentiment
| ELDN | JNJ | |
|---|---|---|
| Short Interest | 0.11% | 0.67% |
ELDN leads on 1 of 1 risk & sentiment factors.
Dig deeper: ELDN overview, ELDN financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.